利索-全球专利检索

  1. 登录
  2. 注册
发明公开
CN110151777A hsa-miR-12462在抗急性髓系白血病中的应用 失效 - 权利终止 转让

hsa-miR-12462在抗急性髓系白血病中的应用
摘要：
本发明属于生物医药领域，具体地涉及hsa-miR-12462在急性髓系白血病治疗中的应用。实验研究表明，在急性髓系白血病发生发展过程中，hsa-miR-12462的表达水平存在明显的变化；在急性髓系白血病和急性髓系白血病细胞中hsa-miR-12462表达水平的上调或下调，可以显著促进或抑制细胞分化进程；hsa-miR-12462能够明显促进抗急性髓系白血病细胞的凋亡。本发明研究结果表明通过上调hsa-miR-12462的表达能够达到治疗急性髓系白血病的目的。基于hsa-miR-12462的功能其可用于制备抗急性髓系白血病药物，本发明为开发新的抗急性髓系白血病的药物提供了重要的基础。
摘要（英）：

The invention belongs to the field of biological medicine, and particularly relates to application of hsa-miR-12462 in treatment of acute myeloid leukemia. Experimental research shows that in the occurrence and development process of acute myeloid leukemia, the expression level of hsa-miR-12462 obviously changes; the increase or decrease of the expression level of hsa-miR-12462 in acute myeloid leukemia and acute myeloid leukemia cells can remarkably promote or inhibit the cell differentiation process; hsa-miR-12462 can obviously promote apoptosis of anti-acute myeloid leukemia cells. The research result shows that the purpose of treating acute myeloid leukemia can be achieved by increasing the expression of hsa-miR-12462. On the basis of the functions of hsa-miR-12462, hsa-miR-12462 can be used for preparing medicines for resisting acute myeloid leukemia, and an important foundation is provided for developing new medicines for resisting acute myeloid leukemia.

公开/授权文献
0/0